Xtant Medical Holdings, Inc.

AMEX:XTNT

Medical - Devices

Healthcare
$0.36 -0.16%

-$0.00 today

Market cap
$50.37M
Beta
-0.17
P/E (TTM)
33.4
EPS (TTM)
$0.01
52W Low $0.40High $0.95

Volume 0.16M

Average 0.16M

XTNT Common Stock Repurchased

Cash spent buying back the company's own shares.

Xtant Medical Holdings, Inc.AMEX: XTNT

Common Stock Repurchased · Q1 FY2026 · quarter ended Mar 2026

Common stock repurchased outflow grows to $0

Q1 FY2026 common stock repurchased was $0, compared with $0 a year earlier. Trailing-twelve-month common stock repurchased was -$120K.

Context

  • Common stock repurchased amounted to 0.0% of revenue in FY2025, unchanged from a year earlier.
  • Common stock repurchased increased in 0 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly common stock repurchased holds near $0 or moves back toward the trailing-twelve-month quarterly average of -$30K.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$0+100.0% QoQ
Last fiscal yearDec 2025
-$65K— YoY
LTMMar 2026
-$120K— YoY
Common Stock Repurchased past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year———
3-year CAGR———
5-year CAGR——
10-year CAGR——

Common Stock Repurchased history

USD · from the cash flow

Latest · FY2025
(65K) USD
Year-over-year change
—

Common Stock Repurchased vs competitors

How XTNT compares with its peers on the latest reported figures

  • XTNT's LTM Mar 2026 common stock repurchased of $120K is the largest of the 8 companies compared; the peer median is $0.
  • Common stock repurchased amounts to 0.1% of revenue for XTNT, versus a peer median of 0.0%.
XTNT Competitors Peer median
Common Stock Repurchased for XTNT and competitors
Company Period LTM YoY 3-year CAGR% of revenue
XTNTXtant Medical Holdings, Inc.LTM Mar 2026$120K ——0.1%
FONRFONAR CorporationLTM Mar 2026$646 -100.0%—0.0%
RCELAVITA Medical, Inc.LTM Mar 2026$0 ——0.0%
LUCDLucid Diagnostics Inc.LTM Mar 2026$0 ——0.0%
APYXApyx Medical CorporationLTM Mar 2026$0 ——0.0%
VANIVivani Medical, Inc.LTM Mar 2026$0 ———
EXOZeXoZymes, Inc.LTM Mar 2026$0 ———
RPIDRapid Micro Biosystems, Inc.LTM Mar 2026$0 ——0.0%
Peer median (excluding XTNT) $0-100.0%—0.0%

Competitors are the stored peer set for XTNT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(4.85M)(8.49M)660K(16.45M)4.97M
Depreciation & Amortization1.33M1.29M3.17M4.22M5.22M
Deferred Income Tax00(1.9M)21K0
Stock-Based Compensation2.21M2.46M2.74M4.12M2.89M
Change in Working Capital793K(2.81M)(3.63M)(5.35M)(3.05M)
Accounts Receivables(319K)(3.94M)(8.74M)(755K)(591K)
Inventory2.62M(1.15M)(1.89M)(2.49M)(2M)
Accounts Payables(332K)875K2.98M1.03M(3.12M)
Other Working Capital(1.18M)1.41M4.01M(3.13M)2.66M
Other Non-Cash Items954K2.2M(10.55M)1.54M2.5M
Operating Cash Flow439K(5.34M)(9.52M)(11.9M)12.55M
Capital Expenditures(2.12M)(1.76M)(1.46M)(4.11M)(2.38M)
Acquisitions (Net)00(23.5M)00
Purchases of Investments00000
Sales of Investments00000
Other Investing Activities225K205K175K383K10.28M
Investing Cash Flow(1.89M)(1.56M)(24.78M)(3.73M)7.9M
Debt Repayment(592K)(291K)6.18M12.43M(9.33M)
Common Stock Issued18.43M9.31M14.01M4.46M0
Common Stock Repurchased0000(65K)
Dividends Paid00000
Other Financing Activities(337K)9.07M(500K)(816K)(175K)
Financing Cash Flow17.5M9.02M19.69M16.07M(9.57M)
Effect of Forex Changes0024K(149K)232K
Net Change in Cash16.05M2.12M(14.58M)298K11.11M
Free Cash Flow(1.68M)(7.11M)(10.97M)(16.01M)10.16M

Xtant Medical Holdings, Inc.

AMEX:XTNT

Intrinsic Alpha fair value

Locked

Current Price

$0.36

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.